Linalool in cancer pharmacology: pharmacokinetic limitations and preclinical cytotoxic evidence for translational development.

Abbas A, Bilal M, Jafar F, Weiskirchen R, Amjad A, Afzal MK, Bibi S, Saleem A, Israr M, Mazhar A, Pandey B

Open source

DOI
10.3389/fphar.2026.1891927
Published
2026
Container
Frontiers in pharmacology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fphar.2026.1891927,
  title = {Linalool in cancer pharmacology: pharmacokinetic limitations and preclinical cytotoxic evidence for translational development.},
  author = {Abbas A and Bilal M and Jafar F and Weiskirchen R and Amjad A and Afzal MK and Bibi S and Saleem A and Israr M and Mazhar A and Pandey B},
  year = {2026},
  journal = {Frontiers in pharmacology},
  doi = {10.3389/fphar.2026.1891927},
  url = {https://doi.org/10.3389/fphar.2026.1891927}
}

RIS

TY  - JOUR
TI  - Linalool in cancer pharmacology: pharmacokinetic limitations and preclinical cytotoxic evidence for translational development.
AU  - Abbas A
AU  - Bilal M
AU  - Jafar F
AU  - Weiskirchen R
AU  - Amjad A
AU  - Afzal MK
AU  - Bibi S
AU  - Saleem A
AU  - Israr M
AU  - Mazhar A
AU  - Pandey B
PY  - 2026
JO  - Frontiers in pharmacology
DO  - 10.3389/fphar.2026.1891927
UR  - https://doi.org/10.3389/fphar.2026.1891927
ER  - 

APA

A, A., M, B., F, J., R, W., A, A., MK, A., S, B., A, S., M, I., A, M., & B, P. (2026). Linalool in cancer pharmacology: pharmacokinetic limitations and preclinical cytotoxic evidence for translational development.. Frontiers in pharmacology. https://doi.org/10.3389/fphar.2026.1891927

Source records